Endocrine therapy for breast cancer

Update on Cancer Therapeutics

Volumn 1, Issue 3, 2006, Pages 285-297

  Heldermon, Coy ^a   Ellis, Matthew ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant therapy; Aromatase inhibitor; Breast cancer; Endocrine therapy; Estrogen receptor; Fulvestrant; Tamoxifen

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GESTAGEN; GONADORELIN DERIVATIVE; GOSERELIN; LETROZOLE; LUBRICATING AGENT; MEDROXYPROGESTERONE; MEGESTROL ACETATE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TOREMIFENE; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; ARTHRALGIA; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; EDEMA; ENDOMETRIUM CANCER; ENZYME INHIBITION; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; FLUID RETENTION; FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; JAUNDICE; LUNG EMBOLISM; MYALGIA; NAUSEA; OBESITY; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA DISCHARGE; VIRILIZATION; VITAMIN D DEFICIENCY; WEIGHT GAIN;

EID: 33748559493     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.08.005     Document Type: Review

References (133)

1. Beatson G.W. On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2 (1896) 104-107
2. Harvey H.A., Santen R.J., Osterman J., Samojlik E., White D.S., and Lipton A. A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 43 6 (1979) 2207-2214
3. Nomura Y., Tashiro H., and Osaki A. Long term survival and the prognostic factors of advanced breast cancer patients treated with adreno-oophorectomy. Breast Cancer Res Treat 33 1 (1995) 47-54
4. Sarfaty G., and Tallis M. Probability of a woman with advanced breast cancer responding to adrenalectomy or hypophysectomy. Lancet 2 7675 (1970) 685-687
5. Hayward J. Cancer of the breast. Treatment of the advanced disease. Br Med J 1 707 (1970) 469-471
6. Lacroix M., and Leclercq G. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. Mol Cell Endocrinol 219 1-2 (2004) 1-7
7. Iwase H., Omoto Y., Toyama T., et al. Clinical significance of AIB1 expression in human breast cancer. Breast Cancer Res Treat 80 3 (2003) 339-345
8. Inoue A., Omoto Y., Yamaguchi Y., Kiyama R., and Hayashi S.I. Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol 32 3 (2004) 649-661
9. Santen R.J., Song R.X., Zhang Z., et al. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr Relat Cancer 10 2 (2003) 111-130
10. Chung Y.L., Sheu M.L., Yang S.C., Lin C.H., and Yen S.H. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 97 3 (2002) 306-312
11. Fornander T., Rutqvist L.E., Cedermark B., et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 8630 (1989) 117-120
12. Jordan V.C., and Assikis V.J. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1 5 (1995) 467-472
13. Rutqvist L.E., and Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85 17 (1993) 1398-1406
14. Gorodeski G.I., Beery R., Lunenfeld B., and Geier A. Tamoxifen increases plasma estrogen-binding equivalents and has an estradiol agonistic effect on histologically normal premenopausal and postmenopausal endometrium. Fertil Steril 57 2 (1992) 320-327
15. Uziely B., Lewin A., Brufman G., Dorembus D., and Mor-Yosef S. The effect of tamoxifen on the endometrium. Breast Cancer Res Treat 26 1 (1993) 101-105
16. Enck R.E., and Rios C.N. Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53 12 (1984) 2607-2609
17. Love R.R., Mazess R.B., Barden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326 13 (1992) 852-856
18. Turken S., Siris E., Seldin D., Flaster E., Hyman G., and Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81 14 (1989) 1086-1088
19. Fornander T., Rutqvist L.E., Sjoberg H.E., Blomqvist L., Mattsson A., and Glas U. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 8 6 (1990) 1019-1024
20. Schapira D.V., Kumar N.B., and Lyman G.H. Serum cholesterol reduction with tamoxifen. Breast Cancer Res Treat 17 1 (1990) 3-7
21. Love R.R., Newcomb P.A., Wiebe D.A., et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82 16 (1990) 1327-1332
22. Bratherton D.G., Brown C.H., Buchanan R., et al. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 50 2 (1984) 199-205
23. Furr B.J., and Jordan V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25 2 (1984) 127-205
24. Furr B.J. Pharmacology of tamoxifen. Scott Med J 25 2 (1980) 141
25. Goldhirsch A., Joss R.A., Leuenberger U., Cavalli F., Ryssel H.J., and Brunner K.W. An evaluation of tamoxifen dose escalation in advanced breast cancer. Am J Clin Oncol 5 5 (1982) 501-503
26. Dehal S.S., and Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57 16 (1997) 3402-3406
27. Dehal S.S., and Kupfer D. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 27 6 (1999) 681-688
28. Physicians' desk reference. 58th ed. (2004), Thomson, Montvale
29. Ward H.W.C. Anti oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. BMJ 1 (1973) 13
30. Tormey D.C., Simon R.M., and Lippman M.E. Evaluation of tamoxifen dose in advanced breast cancer: A progress report. Cancer Treat Rep 60 (1976) 1451
31. Westerberg H., Nordenskjold B., de Schryver A., and Notter G. Anti-oestrogen therapy of advanced mammary carcinoma. Acta Radiol Ther Phys Biol 15 6 (1976) 513-518
32. Morgan Jr. L.R., Schein P.S., Woolley P.V., et al. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat Rep 60 10 (1976) 1437-1443
33. Manni A., Trujillo J.E., Marshall J.S., Brodkey J., and Pearson O.H. Antihormone treatment of stage IV breast cancer. Cancer 43 2 (1979) 444-450
34. Rose C., and Mouridsen H.T. Treatment of advanced breast cancer with tamoxifen. Recent Results Cancer Res 91 (1984) 230-242
35. Ingle J.N., Ahmann D.L., Green S.J., et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304 1 (1981) 16-21
36. Ingle J.N., Krook J.E., Green S.J., et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4 2 (1986) 178-185
37. Muss H.B., Case L.D., Atkins J.N., et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a piedmont oncology association study. J Clin Oncol 12 8 (1994) 1630-1638
38. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 9114 (1998) 1451-1467
39. Sawka C.A., Pritchard K.I., Shelley W., et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA. 1. Breast Cancer Res Treat 44 3 (1997) 211-215
40. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 18 (1998) 1371-1388
41. Holli K., Valavaara R., Blanco G., et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 18 20 (2000) 3487-3494
42. Pyrhonen S., Ellmen J., Vuorinen J., et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 56 2 (1999) 133-143
43. Buzdar A.U., and Hortobagyi G.N. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 16 1 (1998) 348-353
44. Morris C., and Wakeling A. Fulvestrant ('Faslodex')-a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 9 4 (2002) 267-276
45. Howell A. Faslodex (ICI 182780). an oestrogen receptor downregulator. Eur J Cancer 36 Suppl. 4 (2000) S87-S88
46. Osborne C.K., Zhao H., and Fuqua S.A. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18 17 (2000) 3172-3186
47. Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98 2 (2003) 229-238
48. Perey L., Thurlimann B., Hawle H., et al. Fulvestrant ('faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors. Breast Cancer Res Treat 76 (2002) S72 [Abstract 249]
49. Klijn J.G., Beex L.V., Mauriac L., et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92 11 (2000) 903-911
50. Klijn J.G., Blamey R.W., Boccardo F., Tominaga T., Duchateau L., and Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19 2 (2001) 343-353
51. Nicholson R.I., Walker K.J., Turkes A., et al. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J Steroid Biochem 23 5B (1985) 843-847
52. Jackson I.M., Matthews M.J., and Diver J.M. LHRH analogues in the treatment of cancer. Cancer Treat Rev 16 3 (1989) 161-175
53. Taylor C.W., Green S., Dalton W.S., et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16 3 (1998) 994-999
54. Pasqualini J.R., Chetrite G., Blacker C., et al. Concentrations of estrone, estradiol, and estronesulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81 4 (1996) 1460-1464
55. de Jong P., van de Ven J., Nortier H., et al. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res 57 11 (1997) 2109-2111
56. Thorsen T., Tangen M., and Stoa K. Concentrations of endogenous estradiol as related to estradiol receptor sites in breast tumor cytosol. Eur J Cancer Clin Oncol 18 (1982) 333-337
57. Masamura S., Santer S., Gimotty P., George J., and Santen R. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake. Breast Cancer Res Treat 42 (1997) 215-216
58. Lu Q., Nakmura J., Savinov A., et al. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137 7 (1996) 3061-3068
59. Bulun S., Price T., Aitken J., Mahendroo M., and Simpson E. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77 (1993) 1622-1628
60. Bulun S.E., and Simpson E.R. Regulation of aromatase expression in human tissues. Breast Cancer Res Treat 30 1 (1994) 19-29
61. Yue W., Wang J.-P., Hamilton C., Demers L., and Santen R. In situ aromarization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 58 (1998) 927-932
62. Miller W.R., Mullen P., Telford J., and Dixon J.M. Clinical importance of intratumoral aromatase. Breast Cancer Res Treat 49 Suppl 1 (1998) S27-S32 [discussion S33-7]
63. Brodie A.M., and Njar V.C. Aromatase inhibitors and breast cancer. Semin Oncol 23 4 Suppl. 9 (1996) 10-20
64. Geisler J., King N., Dowsett M., et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74 8 (1996) 1286-1291
65. Banting L. Inhibition of aromatase. Prog Med Chem 33 (1996) 147-184
66. Brodie A., Hendrickson J., and Tsai-Morris C. Inactivation of aromatase in vitro by 4-OHA and 4-acetoxyandrostenedione and sustain effects in vivo. Steroids 38 (1981) 696-702
67. Geisler J., Haynes B., Anker G., Dowsett M., and Lonning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 3 (2002) 751-757
68. Rose C. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol 26 4 (2003) S9-S16
69. Kennedy B.J. Massive estrogen administration in premenopausal women with metastatic breast cancer. Cancer 15 (1962) 641-648
70. Peethambaram P.P., Ingle J.N., Suman V.J., Hartmann L.C., and Loprinzi C.L. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 54 2 (1999) 117-122
71. Song R.X., and Santen R.J. Apoptotic action of estrogen. Apoptosis 8 1 (2003) 55-60
72. Helle S.I., Geisler J., Anker G.B., Leirvaag B., Holly J.M., and Lonning P.E. Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer. Br J Cancer 85 2 (2001) 147-151
73. Brunner N., Spang-Thomsen M., and Cullen K. The T61 human breast cancer xenograft: an experimental model of estrogen therapy of breast cancer. Breast Cancer Res Treat 39 1 (1996) 87-92
74. Lonning P.E., Taylor P.D., Anker G., et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67 2 (2001) 111-116
75. Mattsson W. Current status of high dose progestin treatment in advanced breast cancer. Breast Cancer Res Treat 3 2 (1983) 231-235
76. Muss H.B., Paschold E.H., Black W.R., et al. Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA). Semin Oncol 12 1 Suppl. 1 (1985) 55-61
77. Coombes R.C., Perez D., Gazet J.C., Ford H.T., and Powles T.J. Danazol treatment for advanced breast cancer. Cancer Chemother Pharmacol 10 3 (1983) 194-195
78. Muss H.B. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 21 1 (1992) 15-26
79. Schifeling D.J., Jackson D.V., Zekan P.J., and Muss H.B. Fluoxymesterone as third line endocrine therapy for advanced breast cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 15 3 (1992) 233-235
80. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88 21 (1996) 1529-1542
81. Fisher B., Dignam J., Bryant J., and Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 9 (2001) 684-690
82. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16 2 (1998) 453-461
83. Buzdar A.U., Jones S.E., Vogel C.L., Wolter J., Plourde P., and Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79 4 (1997) 730-739
84. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
85. Goss P. The rise and current status of aromatase inhibitors in breast cancer treatment. The 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX (2004), Kluwer Academic Publishers
86. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
87. Coombes R., Hall E., Snowdon C., and Bliss J. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. The 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX (2004), Kluwer Academic Publishers
88. Coleman R., Banks L., Hall E., et al. Intergroup exemestane study: 1 year results of the bone sub-protocol. The 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX (2004), Kluwer Academic Publishers
89. Howell obotATGA. ATAC (arimidex, tamoxifen, alone or in combination) completed treatment analysis: anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. The 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX (2004), Kluwer Academic Publishers
90. Baum M., Buzdar A., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 98 9 (2003) 1802-1810
91. Dixon J.M., Anderson T.J., and Miller W.R. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 38 17 (2002) 2214-2221
92. Dixon J.M., Love C.D., Bellamy C.O., et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66 3 (2001) 191-199
93. Dixon J.M., Jackson J., Renshaw L., and Miller W.R. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 86 3-5 (2003) 295-299
94. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12 11 (2001) 1527-1532
95. Smith I.E. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J Steroid Biochem Mol Biol 86 3-5 (2003) 289-293
96. Buzdar A.U. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen. Expert Rev Anticancer Ther 2 6 (2002) 623-629
97. Mokbel K. Focus on anastrozole and breast cancer. Curr Med Res Opin 19 8 (2003) 683-688
98. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 22 (2005) 5108-5116
99. Semiglazov V.F., Semiglazov V., Ivanov V., et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER-positive breast cancer. 2004 ASCO Annual Meeting. J Clin Oncol (2004)
100. Castiglione-Gertsch M., O'Neill A., Price K.N., et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 95 24 (2003) 1833-1846
101. Honig S.F. Hormonal therapy and chemotherapy. In: Harris J.R., Morrow M., and Lippman M.E. (Eds). Diseases of the breast (1996), Lippincott Williams and Wilkins, Philadelphia, PA 699-734
102. Kuukasjarvi T., Kononen J., Helin H., Holli K., and Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14 9 (1996) 2584-2589
103. Ejlertsen B., Dombernowsky P., Henning M., et al. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). American Society of Clinical Oncology Annual Meeting. J Clin Oncol (1999)
104. Taylor SGt, Gelman R.S., Falkson G., and Cummings F.J. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104 4 (1986) 455-461
105. Howell A., Dodwell D.J., Anderson H., and Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3 8 (1992) 611-617
106. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 11 (2003) 2101-2109
107. Bonneterre J., Buzdar A., Nabholtz J.M., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92 9 (2001) 2247-2258
108. Nabholtz J.M., Bonneterre J., Buzdar A., Robertson J.F., and Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39 12 (2003) 1684-1689
109. Paridaens R., Therasse P., Dirix L., et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)-a randomized phase III trial of the EORTC breast group. 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 515 (2004) [abstract]
110. Thurlimann B., Robertson J.F., Nabholtz J.M., Buzdar A., and Bonneterre J. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39 16 (2003) 2310-2317
111. Howell A., Robertson J.F., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 16 (2002) 3396-3403
112. Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20 16 (2002) 3386-3395
113. Rose C., Vtoraya O., Pluzanska A., et al. Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. 2002 ASCO Annual Meeting. J Clin Oncol (2002) [abstract]
114. Lonning P.E., Bajetta E., Murray R., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18 11 (2000) 2234-2244
115. Jones S., Vogel C., Arkhipov A., et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 17 11 (1999) 3418-3425
116. Thurlimann B., Paridaens R., Serin D., et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 33 11 (1997) 1767-1773
117. Chlebowski R.T., Col N., Winer E.P., et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20 15 (2002) 3328-3343
118. Wolmark N., and Dunn B.K. The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann N Y Acad Sci 949 (2001) 99-108
119. Day R. Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann N Y Acad Sci 949 (2001) 143-150
120. Dunn B.K., and Ford L.G. Breast cancer prevention: results of the national surgical adjuvant breast and bowel project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT). Eur J Cancer 36 Suppl. 4 (2000) S49-S50
121. Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 9336 (2002) 817-824
122. Powles T.J., Tillyer C.R., Jones A.L., et al. Prevention of breast cancer with tamoxifen-an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 26 6 (1990) 680-684
123. Veronesi U., Maisonneuve P., Costa A., et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352 9122 (1998) 93-97
124. Cauley J.A., Norton L., Lippman M.E., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65 2 (2001) 125-134
125. Martino S., Cauley J.A., Barrett-Connor E., et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 23 (2004) 1751-1761
126. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 21 (2003) 4042-4057
127. Raisz L.G. Clinical practice. Screening for osteoporosis. N Engl J Med 353 2 (2005) 164-171
128. Lester J., and Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer 93 Suppl. 1 (2005) S16-S22
129. Lester J., Dodwell D., McCloskey E., and Coleman R. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 31 2 (2005) 115-142
130. Zoledronic acid prevents cancer treatment-induced bone loss. Oncology (Williston Park) 19 3 (2005) 390
131. Margiloff L., Harris S.S., Lee S., Lechan R., and Dawson-Hughes B. Vitamin D status of an outpatient clinic population. Calcif Tissue Int 69 5 (2001) 263-267
132. Harris S.S., Soteriades E., Coolidge J.A., Mudgal S., and Dawson-Hughes B. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab 85 11 (2000) 4125-4130
133. Loprinzi C.L., Pisansky T.M., Fonseca R., et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 16 7 (1998) 2377-2381